Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective

Molecular Therapy

Volumn 25, Issue 5, 2017, Pages 1117-1124

  Rivière, Isabelle ^a   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CAR; genetic engineering; genome editing; immunotherapy; T cells; vectors

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; DNA; LENTIVIRUS VECTOR; RETROVIRUS VECTOR; RNA; CD19 MOLECULE, HUMAN; CHIMERIC PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CELL THERAPY; GENE EDITING; GENE THERAPY; GENETIC ENGINEERING; HUMAN; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; LYMPHOID PROGENITOR CELL; LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; SYNTHETIC BIOLOGY; T LYMPHOCYTE; TRANSPOSON; TUMOR IMMUNOLOGY; BIOLOGICAL THERAPY; CHEMISTRY; CLASSIFICATION; CYTOLOGY; GENE EXPRESSION; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LENTIVIRUS; PATHOLOGY; PROCEDURES; PROTEIN ENGINEERING; RETROVIRIDAE;

ANTIGENS, CD19; CELL ENGINEERING; CELL- AND TISSUE-BASED THERAPY; GENE EXPRESSION; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; LENTIVIRUS; LEUKEMIA; LYMPHOMA; MUTANT CHIMERIC PROTEINS; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; RETROVIRIDAE; T-LYMPHOCYTES;

EID: 85018686063     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.03.034     Document Type: Review

References (154)

1. 1 Eshhar, Z., Bach, N., Fitzer-Attas, C.J., Gross, G., Lustgarten, J., Waks, T., Schindler, D.G., The T-body approach: potential for cancer immunotherapy. Springer Semin. Immunopathol. 18 (1996), 199–209.
2. 2 Sadelain, M., Rivière, I., Brentjens, R., Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3 (2003), 35–45.
3. 3 Irving, B.A., Weiss, A., The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64 (1991), 891–901.
4. 4 Romeo, C., Seed, B., Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64 (1991), 1037–1046.
5. 5 Letourneur, F., Klausner, R.D., T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc. Natl. Acad. Sci. USA 88 (1991), 8905–8909.
6. 6 Eshhar, Z., Waks, T., Gross, G., Schindler, D.G., Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90 (1993), 720–724.
7. 7 Brocker, T., Peter, A., Traunecker, A., Karjalainen, K., New simplified molecular design for functional T cell receptor. Eur. J. Immunol. 23 (1993), 1435–1439.
8. 8 Brocker, T., Karjalainen, K., Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J. Exp. Med. 181 (1995), 1653–1659.
9. 9 Gong, M.C., Latouche, J.B., Krause, A., Heston, W.D., Bander, N.H., Sadelain, M., Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1 (1999), 123–127.
10. 10 Brocker, T., Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96 (2000), 1999–2001.
11. 11 Krause, A., Guo, H.F., Latouche, J.B., Tan, C., Cheung, N.K., Sadelain, M., Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188 (1998), 619–626.
12. 12 Maher, J., Brentjens, R.J., Gunset, G., Rivière, I., Sadelain, M., Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat. Biotechnol. 20 (2002), 70–75.
13. 13 Sadelain, M., Brentjens, R., Rivière, I., The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21 (2009), 215–223.
14. 14 Jensen, M.C., Riddell, S.R., Designing chimeric antigen receptors to effectively and safely target tumors. Curr. Opin. Immunol. 33 (2015), 9–15.
15. 15 van der Stegen, S.J., Hamieh, M., Sadelain, M., The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Discov. 14 (2015), 499–509.
16. 16 Sadelain, M., CAR therapy: the CD19 paradigm. J. Clin. Invest. 125 (2015), 3392–3400.
17. 17 Maus, M.V., June, C.H., Making better chimeric antigen receptors for adoptive T-cell therapy. Clin. Cancer Res. 22 (2016), 1875–1884.
18. 18 Esensten, J.H., Bluestone, J.A., Lim, W.A., Engineering therapeutic T cells: from synthetic biology to clinical trials. Annu. Rev. Pathol. 12 (2017), 305–330.
19. 19 Hinrichs, C.S., Restifo, N.P., Reassessing target antigens for adoptive T-cell therapy. Nat. Biotechnol. 31 (2013), 999–1008.
20. 20 Morello, A., Sadelain, M., Adusumilli, P.S., Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 6 (2016), 133–146.
21. 21 Wang, X., Rivière, I., Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol. Ther. Oncolytics, 3, 2016, 16015.
22. 22 Levine, B.L., Miskin, J., Wonnacott, K., Keir, C., Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4 (2016), 92–101.
23. 23 Wang, X., Rivière, I., Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 22 (2015), 85–94.
24. 24 Brentjens, R.J., Latouche, J.B., Santos, E., Marti, F., Gong, M.C., Lyddane, C., King, P.D., Larson, S., Weiss, M., Rivière, I., Sadelain, M., Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9 (2003), 279–286.
25. 25 Couzin-Frankel, J., Breakthrough of the year 2013. Cancer immunotherapy. Science 342 (2013), 1432–1433.
26. 26 Miller, A.D., Garcia, J.V., von Suhr, N., Lynch, C.M., Wilson, C., Eiden, M.V., Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 65 (1991), 2220–2224.
27. 27 Mavilio, F., Ferrari, G., Rossini, S., Nobili, N., Bonini, C., Casorati, G., Traversari, C., Bordignon, C., Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 83 (1994), 1988–1997.
28. 28 Bunnell, B.A., Muul, L.M., Donahue, R.E., Blaese, R.M., Morgan, R.A., High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA 92 (1995), 7739–7743.
29. 29 Gallardo, H.F., Tan, C., Ory, D., Sadelain, M., Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90 (1997), 952–957.
30. 30 Sadelain, M., Methods for retrovirus-mediated gene transfer into primary T-lymphocytes. Robbins, P.D., (eds.) Gene Therapy Protocols, 1997, Humana Press, 241–248.
31. 31 Onodera, M., Ariga, T., Kawamura, N., Kobayashi, I., Ohtsu, M., Yamada, M., Tame, A., Furuta, H., Okano, M., Matsumoto, S., et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 91 (1998), 30–36.
32. 32 Palù, G., Li Pira, G., Gennari, F., Fenoglio, D., Parolin, C., Manca, F., Genetically modified immunocompetent cells in HIV infection. Gene Ther. 8 (2001), 1593–1600.
33. 33 Deeks, S.G., Wagner, B., Anton, P.A., Mitsuyasu, R.T., Scadden, D.T., Huang, C., Macken, C., Richman, D.D., Christopherson, C., June, C.H., et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5 (2002), 788–797.
34. 34 Bonini, C., Grez, M., Traversari, C., Ciceri, F., Marktel, S., Ferrari, G., Dinauer, M., Sadat, M., Aiuti, A., Deola, S., et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat. Med. 9 (2003), 367–369.
35. 35 Muul, L.M., Tuschong, L.M., Soenen, S.L., Jagadeesh, G.J., Ramsey, W.J., Long, Z., Carter, C.S., Garabedian, E.K., Alleyne, M., Brown, M., et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101 (2003), 2563–2569.
36. 36 Macpherson, J.L., Boyd, M.P., Arndt, A.J., Todd, A.V., Fanning, G.C., Ely, J.A., Elliott, F., Knop, A., Raponi, M., Murray, J., et al. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. J. Gene Med. 7 (2005), 552–564.
37. 37 Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006), 126–129.
38. 38 Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., White, D.E., Wunderlich, J.R., Canevari, S., Rogers-Freezer, L., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12 (2006), 6106–6115.
39. 39 Rivière, I., Brose, K., Mulligan, R.C., Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. USA 92 (1995), 6733–6737.
40. 40 Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., Huls, M.H., Liu, E., Gee, A.P., Mei, Z., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14 (2008), 1264–1270.
41. 41 Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32 (2009), 169–180.
42. 42 Kochenderfer, J.N., Feldman, S.A., Zhao, Y., Xu, H., Black, M.A., Morgan, R.A., Wilson, W.H., Rosenberg, S.A., Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32 (2009), 689–702.
43. 43 Roe, T., Reynolds, T.C., Yu, G., Brown, P.O., Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12 (1993), 2099–2108.
44. 44 Hajihosseini, M., Iavachev, L., Price, J., Evidence that retroviruses integrate into post-replication host DNA. EMBO J. 12 (1993), 4969–4974.
45. 45 Koehne, G., Gallardo, H.F., Sadelain, M., O'Reilly, R.J., Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood 96 (2000), 109–117.
46. 46 Zack, J.A., Arrigo, S.J., Weitsman, S.R., Go, A.S., Haislip, A., Chen, I.S., HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61 (1990), 213–222.
47. 47 Lewis, P.F., Emerman, M., Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 68 (1994), 510–516.
48. 48 Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M., Trono, D., In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996), 263–267.
49. 49 Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L., Charneau, P., HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101 (2000), 173–185.
50. 50 Korin, Y.D., Zack, J.A., Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol. 72 (1998), 3161–3168.
51. 51 Unutmaz, D., KewalRamani, V.N., Marmon, S., Littman, D.R., Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189 (1999), 1735–1746.
52. 52 Cavalieri, S., Cazzaniga, S., Geuna, M., Magnani, Z., Bordignon, C., Naldini, L., Bonini, C., Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102 (2003), 497–505.
53. 53 Humeau, L.M., Binder, G.K., Lu, X., Slepushkin, V., Merling, R., Echeagaray, P., Pereira, M., Slepushkina, T., Barnett, S., Dropulic, L.K., et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol. Ther. 9 (2004), 902–913.
54. 54 Wang, X., Chang, W.C., Wong, C.W., Colcher, D., Sherman, M., Ostberg, J.R., Forman, S.J., Riddell, S.R., Jensen, M.C., A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118 (2011), 1255–1263.
55. 55 Levine, B.L., Humeau, L.M., Boyer, J., MacGregor, R.R., Rebello, T., Lu, X., Binder, G.K., Slepushkin, V., Lemiale, F., Mascola, J.R., et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA 103 (2006), 17372–17377.
56. 56 Mitchell, R.S., Beitzel, B.F., Schroder, A.R., Shinn, P., Chen, H., Berry, C.C., Ecker, J.R., Bushman, F.D., Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol., 2, 2004, E234.
57. 57 Nienhuis, A.W., Dunbar, C.E., Sorrentino, B.P., Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 13 (2006), 1031–1049.
58. 58 Gabriel, R., Schmidt, M., von Kalle, C., Integration of retroviral vectors. Curr. Opin. Immunol. 24 (2012), 592–597.
59. 59 Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C.C., Ranzani, M., Benedicenti, F., Sergi, L.S., Ambrosi, A., Ponzoni, M., et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119 (2009), 964–975.
60. 60 Newrzela, S., Cornils, K., Li, Z., Baum, C., Brugman, M.H., Hartmann, M., Meyer, J., Hartmann, S., Hansmann, M.L., Fehse, B., von Laer, D., Resistance of mature T cells to oncogene transformation. Blood 112 (2008), 2278–2286.
61. 61 Cruz, C.R., Hanley, P.J., Liu, H., Torrano, V., Lin, Y.F., Arce, J.A., Gottschalk, S., Savoldo, B., Dotti, G., Louis, C.U., et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy 12 (2010), 743–749.
62. 62 Scholler, J., Brady, T.L., Binder-Scholl, G., Hwang, W.T., Plesa, G., Hege, K.M., Vogel, A.N., Kalos, M., Riley, J.L., Deeks, S.G., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med., 4, 2012, 132ra53.
63. 63 Oliveira, G., Ruggiero, E., Stanghellini, M.T., Cieri, N., D'Agostino, M., Fronza, R., Lulay, C., Dionisio, F., Mastaglio, S., Greco, R., et al. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Sci. Transl. Med., 7, 2015, 317ra198.
64. 64 Preston, B.D., Poiesz, B.J., Loeb, L.A., Fidelity of HIV-1 reverse transcriptase. Science 242 (1988), 1168–1171.
65. 65 Roberts, J.D., Bebenek, K., Kunkel, T.A., The accuracy of reverse transcriptase from HIV-1. Science 242 (1988), 1171–1173.
66. 66 Ji, J., Loeb, L.A., Fidelity of HIV-1 reverse transcriptase copying a hypervariable region of the HIV-1 env gene. Virology 199 (1994), 323–330.
67. 67 Mansky, L.M., Temin, H.M., Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69 (1995), 5087–5094.
68. 68 De Angioletti, M., Rovira, A., Sadelain, M., Luzzatto, L., Notaro, R., Frequency of missense mutations in the coding region of a eukaryotic gene transferred by retroviral vectors. J. Virol. 76 (2002), 1991–1994.
69. 69 Wang, X., Olszewska, M., Capacio, V., Stefanski, J., Przybylowski, M., Samakoglu, S., Chang, A.H., Sadelain, M., Rivière, I., Quantitative analysis of clinically relevant mutations occurring in lymphoid cells harboring gamma-retrovirus-encoded hsvtk suicide genes. Gene Ther. 15 (2008), 1454–1459.
70. 70 Hackett, P.B., Ekker, S.C., Largaespada, D.A., McIvor, R.S., Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv. Genet. 54 (2005), 189–232.
71. 71 Singh, H., Figliola, M.J., Dawson, M.J., Olivares, S., Zhang, L., Yang, G., Maiti, S., Manuri, P., Senyukov, V., Jena, B., et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS ONE, 8, 2013, e64138.
72. 72 Hackett, P.B., Largaespada, D.A., Switzer, K.C., Cooper, L.J., Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl. Res. 161 (2013), 265–283.
73. 73 Singh, H., Huls, H., Kebriaei, P., Cooper, L.J., A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol. Rev. 257 (2014), 181–190.
74. 74 Zhao, Y., Zheng, Z., Cohen, C.J., Gattinoni, L., Palmer, D.C., Restifo, N.P., Rosenberg, S.A., Morgan, R.A., High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 13 (2006), 151–159.
75. 75 Yoon, S.H., Lee, J.M., Cho, H.I., Kim, E.K., Kim, H.S., Park, M.Y., Kim, T.G., Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther. 16 (2009), 489–497.
76. 76 Rowley, J., Monie, A., Hung, C.F., Wu, T.C., Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. Eur. J. Immunol. 39 (2009), 491–506.
77. 77 Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G., Chew, A., Zhao, Y., Levine, B.L., Albelda, S.M., et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2 (2014), 112–120.
78. 78 Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S., Gregory, P.D., Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11 (2010), 636–646.
79. 79 Sander, J.D., Joung, J.K., CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32 (2014), 347–355.
80. 80 Kim, H., Kim, J.S., A guide to genome engineering with programmable nucleases. Nat. Rev. Genet. 15 (2014), 321–334.
81. 81 Wright, A.V., Nuñez, J.K., Doudna, J.A., Biology and applications of CRISPR systems: harnessing nature's toolbox for genome engineering. Cell 164 (2016), 29–44.
82. 82 Tsai, S.Q., Joung, J.K., Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. Nat. Rev. Genet. 17 (2016), 300–312.
83. 83 Porteus, M., Genome editing: a new approach to human therapeutics. Annu. Rev. Pharmacol. Toxicol. 56 (2016), 163–190.
84. 84 Holt, N., Wang, J., Kim, K., Friedman, G., Wang, X., Taupin, V., Crooks, G.M., Kohn, D.B., Gregory, P.D., Holmes, M.C., Cannon, P.M., Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28 (2010), 839–847.
85. 85 Mandal, P.K., Ferreira, L.M., Collins, R., Meissner, T.B., Boutwell, C.L., Friesen, M., Vrbanac, V., Garrison, B.S., Stortchevoi, A., Bryder, D., et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 15 (2014), 643–652.
86. 86 Tebas, P., Stein, D., Tang, W.W., Frank, I., Wang, S.Q., Lee, G., Spratt, S.K., Surosky, R.T., Giedlin, M.A., Nichol, G., et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370 (2014), 901–910.
87. 87 Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.Q., Reik, A., Chu, V., Paschon, D.E., Zhang, L., Kuball, J., et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18 (2012), 807–815.
88. 88 Torikai, H., Reik, A., Liu, P.Q., Zhou, Y., Zhang, L., Maiti, S., Huls, H., Miller, J.C., Kebriaei, P., Rabinovich, B., et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119 (2012), 5697–5705.
89. 89 Berdien, B., Mock, U., Atanackovic, D., Fehse, B., TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 21 (2014), 539–548.
90. 90 Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies. Cancer Res. 75 (2015), 3853–3864.
91. 91 Schumann, K., Lin, S., Boyer, E., Simeonov, D.R., Subramaniam, M., Gate, R.E., Haliburton, G.E., Ye, C.J., Bluestone, J.A., Doudna, J.A., Marson, A., Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc. Natl. Acad. Sci. USA 112 (2015), 10437–10442.
92. 92 Menger, L., Gouble, A., Marzolini, M.A., Pachnio, A., Bergerhoff, K., Henry, J.Y., Smith, J., Pule, M., Moss, P., Riddell, S.R., et al. TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells. Blood 126 (2015), 2781–2789.
93. 93 Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med., 9, 2017, eaaj2013.
94. 94 Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S.J., Hamieh, M., Cunanan, K.M., Odak, A., Gönen, M., Sadelain, M., Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543 (2017), 113–117.
95. 95 Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C.M., Quigley, M.F., Almeida, J.R., Gostick, E., Yu, Z., Carpenito, C., et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17 (2011), 1290–1297.
96. 96 Gattinoni, L., Klebanoff, C.A., Restifo, N.P., Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12 (2012), 671–684.
97. 97 Gattinoni, L., Zhong, X.S., Palmer, D.C., Ji, Y., Hinrichs, C.S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L.M., et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15 (2009), 808–813.
98. 98 Sathaliyawala, T., Kubota, M., Yudanin, N., Turner, D., Camp, P., Thome, J.J., Bickham, K.L., Lerner, H., Goldstein, M., Sykes, M., et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity 38 (2013), 187–197.
99. 99 Buchholz, V.R., Flossdorf, M., Hensel, I., Kretschmer, L., Weissbrich, B., Gräf, P., Verschoor, A., Schiemann, M., Höfer, T., Busch, D.H., Disparate individual fates compose robust CD8+ T cell immunity. Science 340 (2013), 630–635.
100. 100 Gerlach, C., Rohr, J.C., Perié, L., van Rooij, N., van Heijst, J.W., Velds, A., Urbanus, J., Naik, S.H., Jacobs, H., Beltman, J.B., et al. Heterogeneous differentiation patterns of individual CD8+ T cells. Science 340 (2013), 635–639.
101. 101 Farber, D.L., Yudanin, N.A., Restifo, N.P., Human memory T cells: generation, compartmentalization and homeostasis. Nat. Rev. Immunol. 14 (2014), 24–35.
102. 102 Graef, P., Buchholz, V.R., Stemberger, C., Flossdorf, M., Henkel, L., Schiemann, M., Drexler, I., Höfer, T., Riddell, S.R., Busch, D.H., Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity 41 (2014), 116–126.
103. 103 Gattinoni, L., Klebanoff, C.A., Palmer, D.C., Wrzesinski, C., Kerstann, K., Yu, Z., Finkelstein, S.E., Theoret, M.R., Rosenberg, S.A., Restifo, N.P., Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115 (2005), 1616–1626.
104. 104 Berger, C., Jensen, M.C., Lansdorp, P.M., Gough, M., Elliott, C., Riddell, S.R., Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118 (2008), 294–305.
105. 105 Hinrichs, C.S., Borman, Z.A., Cassard, L., Gattinoni, L., Spolski, R., Yu, Z., Sanchez-Perez, L., Muranski, P., Kern, S.J., Logun, C., et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. USA 106 (2009), 17469–17474.
106. 106 Busch, D.H., Fräßle, S.P., Sommermeyer, D., Buchholz, V.R., Riddell, S.R., Role of memory T cell subsets for adoptive immunotherapy. Semin. Immunol. 28 (2016), 28–34.
107. 107 Sommermeyer, D., Hudecek, M., Kosasih, P.L., Gogishvili, T., Maloney, D.G., Turtle, C.J., Riddell, S.R., Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30 (2016), 492–500.
108. 108 Turtle, C.J., Hanafi, L.A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med., 8, 2016, 355ra116.
109. 109 Turtle, C.J., Hanafi, L.A., Berger, C., Gooley, T.A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T.M., et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126 (2016), 2123–2138.
110. 110 Afzali, B., Lechler, R.I., Hernandez-Fuentes, M.P., Allorecognition and the alloresponse: clinical implications. Tissue Antigens 69 (2007), 545–556.
111. 111 Morgan, R.A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P.F., Zheng, Z., Dudley, M.E., Feldman, S.A., Yang, J.C., Sherry, R.M., et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36 (2013), 133–151.
112. 112 Cameron, B.J., Gerry, A.B., Dukes, J., Harper, J.V., Kannan, V., Bianchi, F.C., Grand, F., Brewer, J.E., Gupta, M., Plesa, G., et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med., 5, 2013, 197ra103.
113. 113 Haque, T., Wilkie, G.M., Jones, M.M., Higgins, C.D., Urquhart, G., Wingate, P., Burns, D., McAulay, K., Turner, M., Bellamy, C., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110 (2007), 1123–1131.
114. 114 Doubrovina, E., Oflaz-Sozmen, B., Prockop, S.E., Kernan, N.A., Abramson, S., Teruya-Feldstein, J., Hedvat, C., Chou, J.F., Heller, G., Barker, J.N., et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119 (2012), 2644–2656.
115. 115 Cruz, C.R., Micklethwaite, K.P., Savoldo, B., Ramos, C.A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A.J., Ito, S., et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122 (2013), 2965–2973.
116. 116 Ghosh, A., Smith, M., James, S.E., Davila, M.L., Velardi, E., Argyropoulos, K.V., Gunset, G., Perna, F., Kreines, F.M., Levy, E.R., et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat. Med. 23 (2017), 242–249.
117. 117 Clarke, S.R., Rudensky, A.Y., Survival and homeostatic proliferation of naive peripheral CD4+ T cells in the absence of self peptide:MHC complexes. J. Immunol. 165 (2000), 2458–2464.
118. 118 Surh, C.D., Sprent, J., Homeostasis of naive and memory T cells. Immunity 29 (2008), 848–862.
119. 119 Awong, G., La Motte-Mohs, R.N., Zúñiga-Pflücker, J.C., Generation of pro-T cells in vitro: potential for immune reconstitution. Semin. Immunol. 19 (2007), 341–349.
120. 120 Zakrzewski, J.L., Kochman, A.A., Lu, S.X., Terwey, T.H., Kim, T.D., Hubbard, V.M., Muriglan, S.J., Suh, D., Smith, O.M., Grubin, J., et al. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat. Med. 12 (2006), 1039–1047.
121. 121 Zakrzewski, J.L., Suh, D., Markley, J.C., Smith, O.M., King, C., Goldberg, G.L., Jenq, R., Holland, A.M., Grubin, J., Cabrera-Perez, J., et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat. Biotechnol. 26 (2008), 453–461.
122. 122 Timmermans, F., Velghe, I., Vanwalleghem, L., De Smedt, M., Van Coppernolle, S., Taghon, T., Moore, H.D., Leclercq, G., Langerak, A.W., Kerre, T., et al. Generation of T cells from human embryonic stem cell-derived hematopoietic zones. J. Immunol. 182 (2009), 6879–6888.
123. 123 Kennedy, M., Awong, G., Sturgeon, C.M., Ditadi, A., LaMotte-Mohs, R., Zúñiga-Pflücker, J.C., Keller, G., T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures. Cell Rep. 2 (2012), 1722–1735.
124. 124 Vizcardo, R., Masuda, K., Yamada, D., Ikawa, T., Shimizu, K., Fujii, S., Koseki, H., Kawamoto, H., Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell 12 (2013), 31–36.
125. 125 Nishimura, T., Kaneko, S., Kawana-Tachikawa, A., Tajima, Y., Goto, H., Zhu, D., Nakayama-Hosoya, K., Iriguchi, S., Uemura, Y., Shimizu, T., et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12 (2013), 114–126.
126. 126 Themeli, M., Kloss, C.C., Ciriello, G., Fedorov, V.D., Perna, F., Gonen, M., Sadelain, M., Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31 (2013), 928–933.
127. 127 Themeli, M., Rivière, I., Sadelain, M., New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 16 (2015), 357–366.
128. 128 Ellebrecht, C.T., Bhoj, V.G., Nace, A., Choi, E.J., Mao, X., Cho, M.J., Di Zenzo, G., Lanzavecchia, A., Seykora, J.T., Cotsarelis, G., et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353 (2016), 179–184.
129. 129 Elinav, E., Waks, T., Eshhar, Z., Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology 134 (2008), 2014–2024.
130. 130 Lee, J.C., Hayman, E., Pegram, H.J., Santos, E., Heller, G., Sadelain, M., Brentjens, R., In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 71 (2011), 2871–2881.
131. 131 Blat, D., Zigmond, E., Alteber, Z., Waks, T., Eshhar, Z., Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol. Ther. 22 (2014), 1018–1028.
132. 132 Levine, A.G., Hemmers, S., Baptista, A.P., Schizas, M., Faire, M.B., Moltedo, B., Konopacki, C., Schmidt-Supprian, M., Germain, R.N., Treuting, P.M., Rudensky, A.Y., Suppression of lethal autoimmunity by regulatory T cells with a single TCR specificity. J. Exp. Med. 214 (2017), 609–622.
133. 133 Boardman, D.A., Philippeos, C., Fruhwirth, G.O., Ibrahim, M.A., Hannen, R.F., Cooper, D., Marelli-Berg, F.M., Watt, F.M., Lechler, R.I., Maher, J., et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am. J. Transplant. 17 (2016), 931–943.
134. 134 Carter, R.H., Fearon, D.T., CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256 (1992), 105–107.
135. 135 Engel, P., Zhou, L.J., Ord, D.C., Sato, S., Koller, B., Tedder, T.F., Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3 (1995), 39–50.
136. 136 Rickert, R.C., Rajewsky, K., Roes, J., Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376 (1995), 352–355.
137. 137 Kochenderfer, J.N., Yu, Z., Frasheri, D., Restifo, N.P., Rosenberg, S.A., Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116 (2010), 3875–3886.
138. 138 Pegram, H.J., Lee, J.C., Hayman, E.G., Imperato, G.H., Tedder, T.F., Sadelain, M., Brentjens, R.J., Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119 (2012), 4133–4141.
139. 139 Davila, M.L., Kloss, C.C., Gunset, G., Sadelain, M., CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS ONE, 8, 2013, e61338.
140. 140 Paszkiewicz, P.J., Fräßle, S.P., Srivastava, S., Sommermeyer, D., Hudecek, M., Drexler, I., Sadelain, M., Liu, L., Jensen, M.C., Riddell, S.R., Busch, D.H., Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J. Clin. Invest. 126 (2016), 4262–4272.
141. 141 Lamers, C.H., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., Gratama, J.W., Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117 (2011), 72–82.
142. 142 Maus, M.V., Haas, A.R., Beatty, G.L., Albelda, S.M., Levine, B.L., Liu, X., Zhao, Y., Kalos, M., June, C.H., T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1 (2013), 26–31.
143. 143 Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., Maric, I., Raffeld, M., Nathan, D.A., Lanier, B.J., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116 (2010), 4099–4102.
144. 144 Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., June, C.H., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3, 2011, 95ra73.
145. 145 Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med., 5, 2013, 177ra38.
146. 146 Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., Stetler-Stevenson, M., Phan, G.Q., Hughes, M.S., Sherry, R.M., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119 (2012), 2709–2720.
147. 147 Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 2014, 224ra25.
148. 148 Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
149. 149 Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., Somerville, R.P., Carpenter, R.O., Stetler-Stevenson, M., Yang, J.C., Phan, G.Q., Hughes, M.S., Sherry, R.M., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33 (2015), 540–549.
150. 150 Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385 (2015), 517–528.
151. 151 Kochenderfer, J.N., Rosenberg, S.A., Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10 (2013), 267–276.
152. 152 Park, J.H., Geyer, M.B., Brentjens, R.J., CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 127 (2016), 3312–3320.
153. 153 Singh, N., Frey, N.V., Grupp, S.A., Maude, S.L., CAR T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia. Curr. Treat. Options Oncol., 17, 2016, 28.
154. 154 Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 368 (2013), 1509–1518.